PLx Pharma (NASDAQ:PLXP) released its earnings results on Friday. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.04, MarketWatch Earnings reports. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.18 million. PLx Pharma had a positive return on equity of 31.27% and a negative net margin of 2,056.16%.
Shares of PLx Pharma stock traded down $0.06 during trading hours on Friday, hitting $4.44. The company’s stock had a trading volume of 13,300 shares, compared to its average volume of 17,006. The company has a market cap of $45.22 million, a PE ratio of -3.29 and a beta of 5.16. The business has a 50 day moving average price of $4.99 and a two-hundred day moving average price of $5.54. PLx Pharma has a 12-month low of $1.00 and a 12-month high of $7.41.
Several equities analysts have recently commented on the company. Zacks Investment Research upgraded PLx Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. ValuEngine downgraded PLx Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold”.
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Featured Article: What is a price target?
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.